Silence Therapeutics PLC (SLNCF) — 6-K Filings

6-K Filings (15)

• Silence Therapeutics Files 6-K Report — Dec 9, 2024 Risk: low
  Silence Therapeutics plc filed a Form 6-K on December 9, 2024, to report information as a foreign private issuer. The filing is for the month of December 2024 a
• Silence Therapeutics Files Form 6-K — Nov 18, 2024 Risk: low
  Silence Therapeutics plc filed a Form 6-K on November 18, 2024, to report information for the month of November 2024. The filing is for a foreign private issuer
• Silence Therapeutics Files Q3 2024 Financials — Nov 14, 2024 Risk: low
  Silence Therapeutics plc filed a 6-K on November 14, 2024, releasing its unaudited financial statements for the periods ending September 30, 2024. The filing in
• Silence Therapeutics Files Q2 2024 Financials — Aug 15, 2024 Risk: low
  Silence Therapeutics plc filed a 6-K on August 15, 2024, presenting its unaudited financial statements for the periods ending June 30, 2024. The filing includes
• Silence Therapeutics Announces Positive Divesiran Trial Results — Jun 27, 2024 Risk: medium
  On June 27, 2024, Silence Therapeutics plc announced positive initial results from its SANRECO Phase 1 repeat dose clinical trial for divesiran (SLN124). Divesi
• Silence Therapeutics Files 6-K, Incorporates Exhibits — Jun 24, 2024 Risk: low
  Silence Therapeutics plc filed a Form 6-K on June 24, 2024, to report information for the month of June 2024. This filing includes Exhibit 99.1, which is incorp
• Silence Therapeutics Files 6-K, Incorporates Exhibits — Jun 20, 2024 Risk: low
  Silence Therapeutics plc filed a Form 6-K on June 20, 2024, incorporating Exhibit 99.1 by reference into its existing Form S-8 registration statements (File Nos
• Silence Therapeutics Shareholders Approve All AGM Resolutions — May 17, 2024 Risk: low
  Silence Therapeutics plc announced on May 17, 2024, that all resolutions presented at its Annual General Meeting were approved by shareholders. The company is i
• Silence Therapeutics Q1 2024 Financials Filed — May 16, 2024 Risk: low
  Silence Therapeutics plc filed a 6-K on May 16, 2024, reporting its unaudited financial statements for the three months ended March 31, 2024. The filing include
• Silence Therapeutics Files May 2024 6-K Report — May 1, 2024 Risk: low
  Silence Therapeutics plc filed a Form 6-K on May 1, 2024, to report its activities for the month of May 2024. The company is incorporated in the UK and its prin
• Silence Therapeutics Files 6-K for Registration Statement Incorporation — Apr 29, 2024 Risk: low
  Silence Therapeutics plc filed a Form 6-K on April 29, 2024, to incorporate by reference exhibits into its existing registration statements on Form S-8. This fi
• Silence Therapeutics Announces AGM Notice — Apr 15, 2024 Risk: low
  Silence Therapeutics plc announced its Notice of Annual General Meeting (AGM) on April 15, 2024, which was published on the company's website. The AGM is schedu
• Silence Therapeutics Files 6-K with Press Release — Mar 13, 2024 Risk: medium
  Silence Therapeutics plc filed a Form 6-K on March 13, 2024, to report a press release dated February 23, 2024. The press release, filed as Exhibit 99.1, likely
• Silence Therapeutics Hits $10M Milestone, Files 6-K — Feb 23, 2024 Risk: low
  Silence Therapeutics plc filed a 6-K report on February 23, 2024, announcing it achieved a $10 million milestone. This report, under Commission File Number 001-
• Silence Therapeutics to Raise $120M via Private ADS Placement — Feb 6, 2024
  Silence Therapeutics plc announced on February 2, 2024, a private placement where it will sell 5,714,286 American Depositary Shares (ADSs) at $21.00 per ADS to

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX